Columbia University said that it admitted a student to its dental school via an "irregular process" that coincided with fundraising solicitations by former faculty and alumni to disgraced financier Jeffrey Epstein https://t.co/VGGdqcbxbh ...

Exclusive: Jennifer Mnookin would be Columbia University’s fourth leader in three years. https://t.co/0WwMtHbkAR ...

Columbia University extended its search for a new president as it seeks to find a permanent replacement after losing two leaders in the past 16 months. https://t.co/HzDnJIqrkd ...

Dan Och’s family office hired an executive from Columbia University’s endowment to manage its investments, joining a wave of billionaires sourcing staff from some of the world’s largest nonprofit organizations https://t.co/8lUIVxYmkK ...

Market Manipulation - Polymarket's activity volume has been significantly inflated by wash trading [1] - Wash trading involves users rapidly buying and selling the same contracts [1] Research Findings - Columbia University researchers conducted a new study on Polymarket's trading activity [1]

Big Tech's Dominance and AI - Big tech companies have entrenched their power, especially in the AI age, raising concerns about their potential to dominate the economy and limit opportunities for others [2][3] - The central question is whether AI will threaten tech platforms or be used by them to solidify their dominance [5] - Government scrutiny is needed to prevent big tech companies from controlling AI challengers and insulating their monopolies [9][10] Antitrust and Competition - The costs of monopolies are increasing extraction from various sectors, such as advertising and Amazon sellers [7][8] - Government should provoke competition among big tech giants to foster innovation and progress [8] - Reverse acquisitions by big tech companies of AI companies require closer examination [9] - Natural monopoly is a self-fulfilling prophecy, and challenging dominant companies is crucial for prosperity and innovation [11][12] AI Investment and Circularity - There are concerns that giant investments in AI are primarily aimed at insulating monopolies rather than improving products [12] - The circularity of investments, where companies reinvest excess cash into their customers, needs further examination as it may inhibit competition [13][14][15] National Security and China - Competition at home is the most important industrial policy for the United States, making companies stronger when facing Chinese competitors [21] - Worshipping monopoly sacrifices the United States' own competitiveness [22]

Columbia University is hiring an administrator to advise the school on how “to support Jewish students”. This seems like a fine idea. But just imagine the Trumpian distress if a college swapped “Jewish” for “black”, “female”, “transgender” or “Palestinian” https://t.co/XKqGeXSJGW ...

Core Insights - Silo Pharma, Inc. has received a Japanese patent for its lead asset SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD), which enhances its intellectual property portfolio [1][2] - The company is collaborating with Columbia University for the development of SPC-15, which is a serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders [2][3] - Silo Pharma's therapeutic focus includes addressing conditions such as PTSD, chronic pain, and central nervous system diseases, with a diverse portfolio of innovative programs [3] Patent and Intellectual Property - The Japan Patent Office granted patent number 7683882 to Columbia University for the invention titled "Prophylactic efficacy of serotonin 4 receptor agonists against stress," which is exclusively licensed to Silo [1] - This patent adds to Silo's international intellectual property portfolio, reinforcing the protection for SPC-15 [2] Product Development - SPC-15 is positioned for potential eligibility under the FDA's streamlined 505(b)(2) regulatory pathway, which could expedite its approval process [2] - The company is conducting preclinical studies in collaboration with Columbia University and holds exclusive global rights for the development and commercialization of SPC-15 [2] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company [3] - The company's portfolio includes other programs such as SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis [3]

Core Viewpoint - Silo Pharma, Inc. has received a patent for its lead asset SPC-15, which is an intranasal treatment for post-traumatic stress disorder (PTSD), enhancing its intellectual property portfolio and supporting clinical trial development plans [1][2][3]. Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [4]. - The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [4]. Product Details - SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders like PTSD and anxiety [3]. - The product has potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway, which could accelerate its approval process [3]. - Silo Pharma collaborates with Columbia University for preclinical studies and holds exclusive global rights for the development and commercialization of SPC-15 [3].

A recent breach of Columbia University’s computer systems compromised personal information of about 870,000 people, including students and applicants https://t.co/QSVzhFn2oV ...